Potential role for estrogen replacement in the treatment of Alzheimer's dementia

Lon S. Schneider, Martin Farlow, Janice M. Pogoda

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

In light of evidence that estrogen replacement therapy (ERT) might affect cholinergic function, we examined possible effects of ERT on clinical and cognitive responses to the cholinesterase inhibitor tacrine in women with Alzheimer's disease (AD). In a previously reported 30-week, randomized, double-blind, placebo-controlled, multicenter clinical trial, 14.5% of 318 women with evaluable data had been receiving ERT prior to randomization. Patients were randomly assigned to receive placebo or one of three ascending dosages of tacrine (maximum dosages of 80 mg/day, 120 mg/day, or 160 mg/day). Women completing the trial receiving ERT and tacrine improved more than women not receiving ERT who were randomized to tacrine or to placebo as assessed by cognitive (p <0.01), clinical (p = 0.02), caregiver (p = 0.006), and mental status (p = 0.07) ratings. Using an intent-to-treat analysis, they improved significantly on cognitive ratings (p = 0.01). These results provide evidence that prior and continuing ERT may enhance response to tacrine in women with AD. Randomized trials are needed.

Original languageEnglish
JournalThe American Journal of Medicine
Volume103
Issue number3 A
DOIs
StatePublished - Sep 22 1997

Fingerprint

Estrogen Replacement Therapy
Tacrine
Alzheimer Disease
Placebos
Therapeutics
Cholinesterase Inhibitors
Controlled Clinical Trials
Random Allocation
Cholinergic Agents
Caregivers
Multicenter Studies

ASJC Scopus subject areas

  • Nursing(all)

Cite this

Potential role for estrogen replacement in the treatment of Alzheimer's dementia. / Schneider, Lon S.; Farlow, Martin; Pogoda, Janice M.

In: The American Journal of Medicine, Vol. 103, No. 3 A, 22.09.1997.

Research output: Contribution to journalArticle

@article{872796d6b21f47daa6e2b3527dd4480b,
title = "Potential role for estrogen replacement in the treatment of Alzheimer's dementia",
abstract = "In light of evidence that estrogen replacement therapy (ERT) might affect cholinergic function, we examined possible effects of ERT on clinical and cognitive responses to the cholinesterase inhibitor tacrine in women with Alzheimer's disease (AD). In a previously reported 30-week, randomized, double-blind, placebo-controlled, multicenter clinical trial, 14.5{\%} of 318 women with evaluable data had been receiving ERT prior to randomization. Patients were randomly assigned to receive placebo or one of three ascending dosages of tacrine (maximum dosages of 80 mg/day, 120 mg/day, or 160 mg/day). Women completing the trial receiving ERT and tacrine improved more than women not receiving ERT who were randomized to tacrine or to placebo as assessed by cognitive (p <0.01), clinical (p = 0.02), caregiver (p = 0.006), and mental status (p = 0.07) ratings. Using an intent-to-treat analysis, they improved significantly on cognitive ratings (p = 0.01). These results provide evidence that prior and continuing ERT may enhance response to tacrine in women with AD. Randomized trials are needed.",
author = "Schneider, {Lon S.} and Martin Farlow and Pogoda, {Janice M.}",
year = "1997",
month = "9",
day = "22",
doi = "10.1016/S0002-9343(97)00257-X",
language = "English",
volume = "103",
journal = "American Journal of Medicine",
issn = "0002-9343",
publisher = "Elsevier Inc.",
number = "3 A",

}

TY - JOUR

T1 - Potential role for estrogen replacement in the treatment of Alzheimer's dementia

AU - Schneider, Lon S.

AU - Farlow, Martin

AU - Pogoda, Janice M.

PY - 1997/9/22

Y1 - 1997/9/22

N2 - In light of evidence that estrogen replacement therapy (ERT) might affect cholinergic function, we examined possible effects of ERT on clinical and cognitive responses to the cholinesterase inhibitor tacrine in women with Alzheimer's disease (AD). In a previously reported 30-week, randomized, double-blind, placebo-controlled, multicenter clinical trial, 14.5% of 318 women with evaluable data had been receiving ERT prior to randomization. Patients were randomly assigned to receive placebo or one of three ascending dosages of tacrine (maximum dosages of 80 mg/day, 120 mg/day, or 160 mg/day). Women completing the trial receiving ERT and tacrine improved more than women not receiving ERT who were randomized to tacrine or to placebo as assessed by cognitive (p <0.01), clinical (p = 0.02), caregiver (p = 0.006), and mental status (p = 0.07) ratings. Using an intent-to-treat analysis, they improved significantly on cognitive ratings (p = 0.01). These results provide evidence that prior and continuing ERT may enhance response to tacrine in women with AD. Randomized trials are needed.

AB - In light of evidence that estrogen replacement therapy (ERT) might affect cholinergic function, we examined possible effects of ERT on clinical and cognitive responses to the cholinesterase inhibitor tacrine in women with Alzheimer's disease (AD). In a previously reported 30-week, randomized, double-blind, placebo-controlled, multicenter clinical trial, 14.5% of 318 women with evaluable data had been receiving ERT prior to randomization. Patients were randomly assigned to receive placebo or one of three ascending dosages of tacrine (maximum dosages of 80 mg/day, 120 mg/day, or 160 mg/day). Women completing the trial receiving ERT and tacrine improved more than women not receiving ERT who were randomized to tacrine or to placebo as assessed by cognitive (p <0.01), clinical (p = 0.02), caregiver (p = 0.006), and mental status (p = 0.07) ratings. Using an intent-to-treat analysis, they improved significantly on cognitive ratings (p = 0.01). These results provide evidence that prior and continuing ERT may enhance response to tacrine in women with AD. Randomized trials are needed.

UR - http://www.scopus.com/inward/record.url?scp=0030873656&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030873656&partnerID=8YFLogxK

U2 - 10.1016/S0002-9343(97)00257-X

DO - 10.1016/S0002-9343(97)00257-X

M3 - Article

C2 - 9344406

AN - SCOPUS:0030873656

VL - 103

JO - American Journal of Medicine

JF - American Journal of Medicine

SN - 0002-9343

IS - 3 A

ER -